Form 4: Kiniksa Pharmaceuticals CEO Sanj K. Patel Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Kiniksa Pharmaceuticals' Chairman and CEO, Sanj K. Patel, executed sales of Class A Common Shares on March 4th and 6th, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Sanj K. Patel, Chairman and CEO of Kiniksa Pharmaceuticals, sold Class A Common Shares on March 4, 2024, and March 6, 2024.
- The sales were executed under a Rule 10b5-1 trading plan established on May 5, 2023.
- On March 4, 2024, 9,406 shares were sold at a weighted average price of $21.31, and 3,336 shares were sold at a price of $22.
- On March 6, 2024, 5,582 shares were sold at a price of $21.
- Following these transactions, Patel directly owns 52,516 Class A Common Shares.
- Patel also indirectly owns shares held by The Anglia 2013 Revocable Trust and The Marina 2016 Irrevocable Trust, totaling 65,012 and 109,795 shares respectively.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock sales by an executive, which is neither particularly positive nor negative.
Industry Context
Sales by executives are a normal part of corporate governance. The use of a 10b5-1 plan indicates that these sales were pre-planned and not based on any inside information.
Stakeholder Impact
- The share sales may have a minor impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 2013-08-15 | Date of The Anglia 2013 Revocable Trust |
| 2016-06-23 | Date of The Marina 2016 Irrevocable Trust |
| 2023-05-05 | Date of Rule 10b5-1 plan execution |
| 2024-03-04 | Date of share sales |
| 2024-03-06 | Date of share sales |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.